secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001193125-24-160703
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients
---------------------------------------------------------------------------

- 100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.
- First allogeneic cellular therapy to show in vivo gamma-delta T cell expansion/persistence at 365 days.
- Favorable safety: no DLTs, CRS, neurotoxicity, or ICANS observed.
- Two patients relapse-free >3.5 years; third nearing 3 years post-transplant.
- Trial expanded at Dose Level 2; FDA Type B meeting planned this summer for potential registrational path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/0001193125-24-160703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/d774911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-160703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer